Synthetic biology has changed, but the way DNA is made largely hasn’t. From mRNA therapeutics and gene editing to protein engineering and advanced vaccines, today’s most important applications demand DNA that is more accurate, more complex, and easier to use, without bacterial constraints. Yet much of the industry still depends on cloning workflows that introduce delays, contamination risk, and unnecessary limits on what can be built and how quickly teams can move. In this talk, we’ll explore why DNA remains one of the field’s most persistent bottlenecks, and why the future of DNA manufacturing will need to move beyond cloning. We’ll look at how cell-free approaches are removing bacterial constraints, and how the field is opening up through both cell-free DNA as a service and more accessible, kit-based assembly models that bring DNA manufacturing closer to the user. Together, these models have the potential to make advanced DNA easier to access, easier to integrate, and better aligned with the pace of modern biological development